Cardiovascular disease (CVD) as defined by the American Heart Association includes
ischaemic heart disease, stroke, heart failure and thromboembolism [
[1]
]. Solid organ transplantation is associated with an increased risk of CVD morbidity
and mortality [
[2]
], a relationship which was first observed in the context of kidney transplantation
by Foley in 1998 [
[3]
]. This manifests clinically as an increased rate of major adverse cardiovascular
events (MACE), defined as the composite of cardiac death, non-fatal myocardial infarction,
non-fatal stroke, unstable angina and heart failure [
[4]
,
- Aldrovandi A.
- Maffei E.
- Seitun S.
- Martini C.
- Berti E.
- Grilli R.
- et al.
Major adverse cardiac events and the severity of coronary atherosclerosis assessed
by computed tomography coronary angiography in an outpatient population with suspected
or known coronary artery disease.
J Thorac Imaging. 2012; 27: 23-28
[5]
].Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Heart, Lung and CirculationAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Heart disease and stroke statistics - 2014 update: a report from the American Heart Association.Circulation. 2014; 129 (e28-e292)
- Perioperative cardiovascular outcomes of non-cardiac solid organ transplant surgery.Eur Heart J Qual Care Clin Outcomes. 2019; 5: 72-78
- Clinical epidemiology of cardiovascular disease in chronic renal disease.Am J Kidney Dis. 1998; 32: S112-S119
- Major adverse cardiac events and the severity of coronary atherosclerosis assessed by computed tomography coronary angiography in an outpatient population with suspected or known coronary artery disease.J Thorac Imaging. 2012; 27: 23-28
- Association of major adverse cardiac events up to 5 years in patients with chest pain without significant coronary artery disease in the Korean population.J Am Heart Assoc. 2019; 8: e010541
- Survival improvement among patients with end-stage renal disease: trends over time for transplant recipients and wait-listed patients.J Am Soc Nephrol. 2001; 12: 1293-1296
- Cardiovascular mortality following liver transplantation: predictors and temporal trends over 30 years.Eur Heart J Qual Care Clin Outcomes. 2020; 6: 243-253
- Trends in the causes of death among kidney transplant recipients in the United States (1996–2014).Am J Nephrol. 2018; 48: 472-481
- Mortality after lung transplantation: a single-centre cohort analysis.Transpl Int. 2020; 33: 130-141
- Cumulative risk of cardiovascular events after orthotopic liver transplantation.Liver Transpl. 2012; 18: 370-375
- Cardiac allograft vasculopathy after heart transplantation: risk factors and management.J Heart Lung Transplant. 2004; 23: S187-S193
- Cardiovascular disease in patients with renal transplantation.Rev Cubana Med. 2014; 53: 37-49
- Transplant coronary artery disease.JACC Cardiovasc Interv. 2010; 3: 367-377
- Multivessel coronary artery disease predicts mortality, length of stay, and pressor requirements after liver transplantation.Liver Transpl. 2010; 16: 1242-1248
- Predicting coronary heart disease after kidney transplantation: patient outcomes in renal transplantation (PORT) study.Am J Transpl. 2010; 10: 338-353
- New risk factors for atherosclerosis and patient risk assessment.Circulation. 2004; 109 (III15–9)
- The external validation of the cardiovascular risk equation for renal transplant recipients: Applications to BENEFIT and BENEFIT-EXT trials.Transplantation. 2013; 95: 142-147
- Anti-HLA I antibodies induce VEGF production by endothelial cells, which increases proliferation and paracellular permeability.Int J Biochem Cell Biol. 2009; 41: 2422-2430
- Anti-HLA class I antibodies transduce signals in endothelial cells resulting in FGF receptor translocation, down-regulation of ICAM-1 and cell proliferation. Transplantation Proceedings.Transplant Proc. 2001; 33: 311
- Circulating de novo donor specific antibodies and carotid intima-media thickness in pediatric kidney transplant recipients.a pilot study. Front Pediatr. 2020; 8: 17
- Antibody-mediated rejection: a review.Ochsner J. 2017; 17: 46-55
- A 2018 reference guide to the Banff classification of renal allograft pathology.Transplantation. 2018; 102: 1795-1814
- HLA Class II antibodies at the time of kidney transplantation and cardiovascular outcome: a retrospective cohort study.Transplantation. 2020; 104: 823-834
- Determinants and outcomes of accelerated arteriosclerosis: major impact of circulating antibodies.Circ Res. 2015; 117: 470-482
- Post-transplant C-reactive protein monitoring can predict chronic allograft nephropathy.Clin Transplant. 2004; 18: 722-725
- Circulating and intrapulmonary c-reactive protein: a predictor of bronchiolitis obliterans syndrome and pulmonary allograft outcome.J Heart Lung Transplant. 2009; 28: 799-807
- Cardiac allograft vasculopathy: diagnosis, therapy, and prognosis.Croat Med J. 2014; 55: 562-576
- Repeated episodes of thrombosis as a potential mechanism of plaque progression in cardiac allograft vasculopathy.Eur Heart J. 2013; 34: 2905-2915
- The clinical impact of donor-specific antibodies in heart transplantation.Transplant Rev. 2018; 32: 207-217
- Prevalence and clinical correlates of coronary artery disease among new dialysis patients in the United States: a cross-sectional study.J Am Soc Nephrol. 2001; 12: 1516-1523
- High prevalence of occult coronary artery stenosis in patients with chronic kidney disease at the initiation of renal replacement therapy: an angiographic examination.J Am Soc Nephrol. 2005; 16: 1141-1148
- A propensity score–matched analysis indicates screening for asymptomatic coronary artery disease does not predict cardiac events in kidney transplant recipients.Kid Int. 2021; 99: 431-442
- Non-invasive cardiac stress studies may not offer significant benefit in pre-kidney transplant evaluation: A retrospective cohort study.PLoS One. 2020; 15: e0240912
- Coronary artery disease and its risk factors in patients presenting for liver transplantation.J Clin Anesth. 2013; 25: 618-623
- Evolution of causes and risk factors for mortality post-liver transplant: results of the NIDDK long-term follow-up study.Am J Transplant. 2010; 10: 1420-1427
- Cardiovascular disease after liver transplantation: when, what, and who is at risk.Liver Transpl. 2015; 21: 889-896
- Inflammation, atherosclerosis, and coronary artery disease.N Engl J Med. 2005; 352: 1685-1695
- Late failing heart allografts: pathology of cardiac allograft vasculopathy and association with antibody-mediated rejection.Am J Transplant. 2016; 16: 111-120
- Pathology of Lung Rejection: Cellular and Humoral Mediated. Lung Transplantation, Springer International Publishing.2018: 209-230
- 2016 Comprehensive update of the Banff Working Group on Liver Allograft Pathology: introduction of antibody-mediated rejection.Am J Transplant. 2016; 16: 2816-2835
- Diagnosis of renal transplant rejection: Banff classification and beyond.Kidney Res Clin Pract. 2020; 39: 17-31
- Management of the Failing Kidney Transplant British Transplantation Society Guidelines. 2014
- Renal association clinical practice guideline in post-operative care in the kidney transplant recipient.BMC Nephrol. 2017; 18: 174
- Non-immune risk predictors of cardiac allograft vasculopathy: results from the U.S. organ procurement and transplantation network.Int J Cardiol. 2021; 331: 57-62
- Impact of donor-specific antibodies on the outcomes of kidney graft: pathophysiology, clinical, therapy.World J Transplant. 2014; 4: 1-17
- Minimising cold ischaemic time is essential in cardiac death donor-associated liver transplantation.HPB (Oxford). 2011; 13: 411-416
- Protective effect of carbon monoxide in transplantation.J Cell Mol Med. 2006; 10: 650-671
- Application of Heme oxygenase-1, carbon monoxide and biliverdin for the prevention of intestinal ischemia/reperfusion injury.J Clin Biochem Nutr. 2008; 42: 78-88
- Everolimus depletes plaque macrophages, abolishes intraplaque neovascularization and improves survival in mice with advanced atherosclerosis.Vascul Pharmacol. 2019; 113: 70-76
- Cyclosporin A and atherosclerosis - Cellular pathways in atherogenesis.Pharmacol Ther. 2010; 128: 106-118
- Immune and nonimmune predictors of cardiac allograft vasculopathy onset and severity: multivariate risk factor analysis and role of immunosuppression.Am J Transplant. 2004; 4: 962-970
- Advancing immunosuppression therapy to counter the progression of cardiac allograft vasculopathy.J Card Fail. 2005; 11: 137-141
- Suppressive effects of conversion from mycophenolate mofetil to everolimus for the development of cardiac allograft vasculopathy in maintenance of heart transplant recipients.Int J Cardiol. 2016; 203: 307-314
- Calcineurin inhibitors cyclosporine A and tacrolimus induce vascular inflammation and endothelial activation through TLR4 signaling.Sci Rep. 2016; 6 (1 2016;6:1–16)
- Cyclosporine withdrawal improves long-term graft survival in renal transplantation.Transplantation. 2009; 87: 1877-1883
- A phase III study of Belatacept-based immunosuppression Regimens versus Cyclosporine in Renal Transplant Recipients (BENEFIT Study).Am J.Transplant. 2010; 10: 535-546
- Steroid or tacrolimus withdrawal in renal transplant recipients using sirolimus.Int Urol Nephrol. 2011; 43 (4 2011;43:1221-1228)
- Everolimus initiation with early calcineurin inhibitor withdrawal in de novo heart transplant recipients: three-year results from the randomized SCHEDULE Study.Am J Transplant. 2016; 16: 1238-1247
- Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR study.Am J Transplant. 2007; 7: 560-570
- Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: results of a five-year, prospective, randomized study.J Am Soc Nephrol. 2005; 16: 2234-2240
- Graft and patient survival in kidney transplant recipients selected for de novo steroid-free maintenance immunosuppression.Am J Transplantat. 2009; 9: 160-168
- Early steroid withdrawal or tacrolimus minimization versus standard immunosuppression in renal transplant recipients: the ALLEGRO trial [abstract].Am J Transplant. 2018; : 18
- Impact of statin use after heart transplantation.Circ Heart Fail. 2016; 9: e003265
- The impact of coronary artery disease and statins on survival after liver transplantation.Liver Transpl. 2019; 25: 1514-1523
- Statin toxicity: mechanistic insights and clinical implications.Circ Res. 2019; 124: 328-350
- Clinical controversy in transplantation: tacrolimus versus cyclosporine in statin drug interactions.Ann Pharmacother. 2020; 54: 171-177
- Statins for kidney transplant recipients.Nephrology (Carlton). 2015; 20: 304-305
- Safety and tolerability of high-intensity statin therapy in heart transplant patients receiving immunosuppression with tacrolimus.Clin Transplant. 2019; 33: e13454
- Intensity-dependent benefit of statins in survival among prospective kidney transplant patients.Am J Cardiol. 2019; 123: 254-259
- Early aspirin use, allograft rejection, and cardiac allograft vasculopathy in heart transplantation.Clinl Transplant. 2021; (ctr.14424)
- Outcome Analysis of Aspirin in Liver Transplantation - Full Text View - ClinicalTrials.gov n.d.https://clinicaltrials.gov/ct2/show/NCT04327427Date accessed: July 29, 2021
Article info
Publication history
Published online: November 27, 2021
Accepted:
September 9,
2021
Received in revised form:
August 5,
2021
Received:
July 1,
2021
Footnotes
All authors take responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation.
Identification
Copyright
© 2021 Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ). Published by Elsevier B.V. All rights reserved.
